Abstract:Clostridium difficile is a bacterial pathogen that causes serious and potentially fatal inflammatory disease of the colon. One strategy for targeting C. difficile infection is to development treatments that target bacterial virulence. Anti‐virulence strategies to treat C. difficile infection are attractive options to antibiotic therapy because the human microbiota is spared and damage to host tissue is minimized. The Tcd toxins, TcdA and TcdB, are the major virulence factors produced by C. difficile and mediate host cytotoxicity by glucosylating and inactivating Rho family GTPases using UDP‐glucose as a glucosyl donor. Glucosylation of Rho GTPases leads to cell rounding and eventually cell death. We used kinetic isotope effects (KIEs) and transition state theory to solve the transition state structure of the glycosyltransferase domain of TcdB (TcdB‐GTD). This permits the design of transition state analogues which are potent enzyme inhibitors. KIEs compare the chemical steps of enzymatic reaction rates with isotopically labeled substrates and unlabeled substrates and provide critical information on the catalytic mechanism, bond lengths and geometry at the transition state. KIE analysis on the glycohydrolase reaction of TcdB‐GTD supported the formation of a late, dissociative glucocation‐like transition state where positive charge develops on the anomeric carbon. Glucocationic transition states are best mimicked by cationic nitrogen groups at or near the anomeric carbon. Iminosugars contain a nitrogen atom in the sugar ring in place of oxygen and mimic glucocationic transition states. We tested iminosugars for inhibition of TcdB‐GTD and TcdA‐GTD. Isofagomine (Ki TcdB‐GTD = 1.4 µM and Ki TcdA‐GTD = 0.24 µM) and noeuromycin (Ki TcdB‐GTD = 10.6 µM and Ki TcdA‐GTD = 4.7 µM) were the most potent iminosugars identified. Isofagomine and noeuromycin were shown to exhibit an uncompetitive mechanism of inhibition suggesting that both iminosugars act by binding to the enzyme‐UDP complex. Isothermal titration calorimetry experiments with TcdB‐GTD supported this finding where isofagomine and noeuromycin could only bind to TcdB‐GTD in the presence of UDP with Kd = 0.133 µM and Kd = 0.4 µM respectively. In addition, the X‐ray crystal structure of TcdB‐GTD in complex with either Isofagomine or noeuromycin with UDP revealed the formation of an ion‐pair interaction between the cationic nitrogen atom of the iminosugar and the β‐phosphate of UDP. Finally, we confirmed that isofagomine and noeuromycin could prevent Tcd toxin‐induced cytotoxicity of IMR90 cells. Firstly, both iminosugars were able to prevent Tcd toxin‐induced cell rounding as visualized by light microscopy. Secondly, Western blot analysis of Tcd toxin treated IMR90 cell lysates revealed that both isofagomine and noeuromycin could prevent glucosylation of Rac1 by Tcd toxin. Isofagomine and noeuromycin are effective in preventing Tcd toxin action. Transition state analogues against TcdA and TcdB have the potential to be used as treatments for C. difficile infections.

A Novel Multivalent, Single-Domain Antibody Targeting Tcda and Tcdb Prevents Fulminant Clostridium Difficile Infection in Mice

Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo

A Chimeric Toxin Vaccine Protects Against Primary and Recurrent Clostridium Difficile Infection

Mechanisms of Protection Against Clostridium Difficile Infection by the Monoclonal Antitoxin Antibodies Actoxumab and Bezlotoxumab

Structural Basis for Binding of Neutralizing Antibodies to Clostridioides difficile Binary Toxin

Oral Immunization with Nontoxigenic Clostridium Difficile Strains Expressing Chimeric Fragments of TcdA and TcdB Elicits Protective Immunity Against C. Difficile Infection in Both Mice and Hamsters.

De novo design of mini-protein binders broadly neutralizing Clostridioides difficile toxin B variants

Delivery of a therapeutic antibody to the lower gastrointestinal tract for the treatment of <i>Clostridium difficile</i> infection (CDI)

Enhanced immunogenicity of a Clostridioides difficile TcdB vaccine adjuvanted with a synthetic dual-TLR ligand adjuvant.

A Novel Bacteriophage Lysin-Human Defensin Fusion Protein is Effective in Treatment of Clostridioides Difficile Infection in Mice

Protection Against Clostridioides Difficile Disease by a Naturally Avirulent C. Difficile Strain

Preparation and preliminary application of monoclonal antibodies to the receptor binding region of Clostridium difficile toxin B.

Development of Multi-epitope Mrna Vaccine Against Clostridioides Difficile Using Reverse Vaccinology and Immunoinformatics Approaches

<i>Akkermansia muciniphila</i> Ameliorates <i>Clostridioides difficile</i> Infection in Mice by Modulating the Intestinal Microbiome and Metabolites

Characterization and development of new anti‐toxins targeting Clostridium difficile

CDBN-YGXZ, a Novel Small-Molecule Drug, Shows Efficacy against <i>Clostridioides difficile</i> Infection and Recurrence in Mouse and Hamster Infection Models

Immunoinformatics Approach Toward the Introduction of a Novel Multi-Epitope Vaccine Against Clostridium Difficile

The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Clostridium difficile Infection

A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection

A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile

Critical Roles of Clostridium Difficile Toxin B Enzymatic Activities in Pathogenesis